Regulation of Preimplantation Genetic Diagnosis (PGD) Approval in China

1. Meaning and Legal Framework

Preimplantation Genetic Diagnosis (PGD), now commonly called preimplantation genetic testing for monogenic disorders (PGT-M), is a reproductive technology used during in-vitro fertilisation (IVF). Embryos are genetically tested before implantation to identify particular inherited diseases. Preimplantation genetic testing also includes screening for chromosomal abnormalities, commonly called PGT-A.

In China, PGD is regulated through a combination of health-administration rules, licensing requirements, ethical review, and assisted-reproduction standards. The principal authority is the National Health Commission (NHC), which supervises medical institutions providing assisted reproductive technology (ART).

The central legal framework includes:

Measures for the Administration of Human Assisted Reproductive Technology (2001): Establish institutional approval and supervision requirements for assisted reproduction.

Ethical Principles for Human Assisted Reproductive Technology and Human Sperm Banks (2003): Govern the ethical use of reproductive technologies.

Technical Specifications for Human Assisted Reproductive Technology (2019 revision): Establish technical and clinical requirements for ART services.

Administrative Measures for the Approval of Human Assisted Reproductive Technology (2001): Provide an approval framework for institutions undertaking ART.

Civil Code of the People's Republic of China (2021): Provides broader protection for personality rights, privacy, and personal information, relevant to reproductive and genetic data.

These rules mean that a clinic cannot lawfully offer PGD simply because it possesses genetic-testing equipment. It must operate within the authorised ART framework and satisfy the applicable requirements for the particular technology.

2. Approval Procedure for PGD in China

The approval process primarily concerns the medical institution and its authorised reproductive services. It is not necessarily a separate government application for every embryo or every patient.

Step 1: Institutional licensing. A hospital must obtain the relevant approval to provide human assisted reproductive technology. PGD/PGT services must fall within the institution's authorised scope.

Step 2: Clinical eligibility. PGD is principally intended to prevent the transmission of serious hereditary diseases or address recognised genetic indications. The clinical team evaluates the couple's medical history, genetic findings, and reproductive circumstances.

Step 3: Ethical review and informed consent. The institution must follow applicable ethical-review requirements, explain the procedure's limitations and risks, and obtain informed consent. Genetic testing cannot guarantee a healthy child.

Step 4: Laboratory and clinical standards. Embryo biopsy, genetic analysis, quality control, embryo handling, and clinical follow-up must comply with applicable technical requirements. Prenatal confirmation may still be recommended because PGT can produce inconclusive or incorrect results.

Step 5: Regulatory supervision. Health authorities may inspect institutions, review compliance, and impose administrative sanctions for unauthorised reproductive services or other violations.

3. Restrictions on the Use of PGD

China's framework does not treat PGD as an unrestricted method for selecting desirable characteristics.

Disease prevention: Testing for serious inherited conditions may be permitted when clinically justified and performed through authorised services.

Sex selection: Selecting an embryo's sex for non-medical reasons is prohibited under China's assisted-reproduction rules. Narrow medical exceptions may apply where necessary to prevent sex-linked genetic disease.

Non-medical enhancement: PGD should not be treated as authorisation to select embryos for intelligence, appearance, or other preferred traits.

Embryo gene editing: PGD approval does not authorise genetic modification of embryos. Testing an embryo and altering its genome are legally distinct activities.

Research use: Research involving embryos or genetic material may trigger additional ethical and regulatory requirements.

4. Relevant Cases and Legal Precedents

Directly reported Chinese judgments specifically deciding the licensing or approval of PGD are limited. The following cases are relevant to the broader legal framework, but they should not be misrepresented as PGD licensing decisions.

A. He Jiankui Case (2019)

Chinese researcher He Jiankui announced the birth of children whose genomes had been edited using CRISPR technology. The Shenzhen Nanshan District People's Court convicted him of illegal medical practice in December 2019 and sentenced him to three years' imprisonment and a fine of RMB 3 million.

Legal significance: The case demonstrates that reproductive biotechnology must comply with medical licensing, ethical requirements, and applicable legal restrictions. It concerns germline gene editing, not ordinary PGD, and does not establish that PGD itself is prohibited.

B. Huang v. Huang (2014) — Surrogacy-Related Litigation

Chinese litigation involving surrogacy and disputes over parental status illustrates the difficulties that arise when reproductive arrangements fall outside established regulatory frameworks. However, without a verified judgment citation, a particular case name or holding should not be relied upon as a binding PGD precedent.

Legal significance: Disputes involving assisted reproduction must be analysed through the applicable family, civil, and administrative laws rather than assuming that a reproductive procedure automatically establishes parental rights.

C. Chinese Administrative Enforcement

Health authorities have taken enforcement action against unauthorised assisted-reproduction services and prohibited non-medical sex selection. Such administrative enforcement is important in understanding PGD regulation, although a specific published judgment should be cited before attributing a precise holding to a court.

5. Conclusion

China regulates PGD through institutional licensing, clinical eligibility, technical standards, ethical review, and restrictions on non-medical sex selection. The decisive question is whether an authorised institution performs the procedure for a legitimate clinical purpose under applicable rules. PGD approval does not permit embryo gene editing or unrestricted genetic selection.

For legal research, distinguish binding legislation, administrative regulations, ministerial rules, and court judgments. The He Jiankui judgment is a genuine criminal precedent concerning reproductive gene editing, but a definitive case-law analysis of PGD approval requires verified Chinese judgments specifically addressing reproductive-service licensing or genetic diagnosis.